Pharmacological control of platelet function

被引:32
作者
Clutton, P
Folts, JD
Freedman, JE
机构
[1] Georgetown Univ, Med Ctr, Dept Med & Pharmacol, Washington, DC 20007 USA
[2] Univ Wisconsin, Madison, WI USA
关键词
platelets; thrombosis; aspirin; glycoprotein IIb/IIIa; platelet inhibitors;
D O I
10.1006/phrs.2001.0861
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Advancement in the understanding of the mechanisms of platelet activation, as well as the development of new techniques for studying platelet function, have led to the availability of new classes of platelet inhibiting drugs. Initially, characterization of arachidonic acid metabolism in platelets furthered an understanding of the utility of cyclooxygenase inhibitors, most notably aspirin. The discovery and characterization of platelet receptors such as the adenosine diphosphate (ADP) receptor and glycoprotein IIb/IIIa has been associated with the development of novel classes of anti-platelet drug, such as thienopyridine derivatives and glycoprotein IIb/IIIa receptor antagonists, respectively. Future development in receptor pathway inhibitors also includes glycoprotein Ib/IX as well as the potential use of platelet signaling pathway inhibitors. (C) 2001 Academic Press.
引用
收藏
页码:255 / 264
页数:10
相关论文
共 135 条
[1]   SOLUTION STRUCTURE OF KISTRIN, A POTENT PLATELET-AGGREGATION INHIBITOR AND GP-IIB-IIIA ANTAGONIST [J].
ADLER, M ;
LAZARUS, RA ;
DENNIS, MS ;
WAGNER, G .
SCIENCE, 1991, 253 (5018) :445-448
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]   CYCLIC RGD PEPTIDE ANALOGS AS ANTIPLATELET ANTITHROMBOTICS [J].
BARKER, PL ;
BULLENS, S ;
BUNTING, S ;
BURDICK, DJ ;
CHAN, KS ;
DEISHER, T ;
EIGENBROT, C ;
GADEK, TR ;
GANTZOS, R ;
LIPARI, MT ;
MUIR, CD ;
NAPIER, MA ;
PITTI, RM ;
PADUA, A ;
QUAN, C ;
STANLEY, M ;
STRUBLE, M ;
TOM, JYK ;
BURNIER, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) :2040-2048
[4]   PREVENTION OF OCCLUSIVE CORONARY-ARTERY THROMBOSIS BY A MURINE MONOCLONAL-ANTIBODY TO PORCINE VONWILLEBRAND-FACTOR [J].
BELLINGER, DA ;
NICHOLS, TC ;
READ, MS ;
REDDICK, RL ;
LAMB, MA ;
BRINKHOUS, KM ;
EVATT, BL ;
GRIGGS, TR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :8100-8104
[5]  
CADROY Y, 1994, BLOOD, V83, P3218
[6]   ASPIRIN, SULFINPYRAZONE, OR BOTH IN UNSTABLE ANGINA - RESULTS OF A CANADIAN MULTICENTER TRIAL [J].
CAIRNS, JA ;
GENT, M ;
SINGER, J ;
FINNIE, KJ ;
FROGGATT, GM ;
HOLDER, DA ;
JABLONSKY, G ;
KOSTUK, WJ ;
MELENDEZ, LJ ;
MYERS, MG ;
SACKETT, DL ;
SEALEY, BJ ;
TANSER, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) :1369-1375
[7]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[8]   Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial [J].
Cannon, CP ;
McCabe, CH ;
Wilcox, RG ;
Langer, A ;
Caspi, A ;
Berink, P ;
Lopez-Sendon, J ;
Toman, J ;
Charlesworth, A ;
Anders, RJ ;
Alexander, JC ;
Skene, A ;
Braunwald, E .
CIRCULATION, 2000, 102 (02) :149-156
[9]  
Cattaneo M, 1997, THROMB HAEMOSTASIS, V77, P986
[10]  
CATTANEO M, 1991, THROMB HAEMOSTASIS, V66, P694